NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”), of the important April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...

Building the Future of Eye Care Q4 & Full Year 2025 Financial Results February 2026 Vivian, an XDEMVY patient. World-Class Leadership Team With Proven Track Record of Success 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only Bobby Azamian, MD, PhD CEO & Chairman Aziz Mottiwala Chief Commercial Officer Sesha Neervannan, PhD Chief Operating Officer Jeff Farrow Chief Financial & Strategy Officer Forward-looking Statements This presentation contains forward-looking statements that involve risks and unce ...

Fourth Quarter and Full Year 2025 Earnings Q4'25 and FY'25 Earnings Agenda: Alexander Hardy Chief Executive Officer Brian Mueller Chief Financial Officer Cristin Hubbard Chief Commercial Officer February 23, 2026 Forward-Looking Statements This presentation and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expect ...

Fourth Quarter and Full Year 2025 Earnings Call F E B R U A R Y 2 3 , 2 0 2 6 ©2026 Myriad Genetics, Inc. Forward-looking statements and Non-GAAP financial measures Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are based on management's current expectations and the actual events or results may differ materially and adv ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- From a closing price of $2.31 on December 26, 2025, Mereo BioPharma Group plc (NASDAQ: MREO) shares plummeted to $0.29 on December 29, 2025—a decline of more than 87.7%—as corrective disclosures allegedly revealed that neither the ORBIT nor COSMIC Phase 3 studies achieved statistical significance. Investors have until April 6, 2026 to seek lead plaintiff status. See if you can recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-75 ...

New York, New York--(Newsfile Corp. - February 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contin ...

Core Viewpoint - Gossamer Bio Inc. announced the top line results from the PROSERA Phase III study of seralutinib for pulmonary arterial hypertension, indicating significant progress in their clinical development pipeline [2]. Group 1: Study Results - The PROSERA study is a Phase III clinical trial focused on seralutinib, which targets pulmonary arterial hypertension [2]. - The results from the study were released in a press release available on the company's Investors section of their website [2]. Group 2: Company Leadership - The call featured Gossamer executives including COO & CFO Bryan Giraudo, along with other key team members such as Faheem Hasnain, Dr. Richard Aranda, Bob Smith, Dr. Rob Roscigno, and Caryn Peterson [2].

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory filings indicated that Nvidia had divested all its stake in the company. Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts The giant semiconductor company exited its previous holding of 7.71 million shares in Recursion Pharmaceuticals, which is making a name for itself by levera ...

Shares of cancer-detection firm Grail (NASDAQ: GRAL) fell by half in last Friday's trading session. That's quite a turnabout after the company's share price more than quintupled in 2025, from about $19 a share in January to $110 in November. Last week shares of the California-based biotech were trading at around $102. Today they're priced at $49. What happened? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" ...

EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. ET. The fires ...